- Home
- RAND vs LITS Comparison
RAND vs LITS Comparison
Compare RAND & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAND | LITS |
|---|---|---|
| Founded | 1969 | 2000 |
| Country | United States | United States |
| Employees | N/A | 4 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 25.7M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | RAND | LITS |
|---|---|---|
| Price | $10.38 | $0.98 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.8K | ★ 144.8K |
| Earning Date | 05-06-2026 | 05-19-2026 |
| Dividend Yield | ★ 10.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.00 | $0.69 |
| 52 Week High | $18.15 | $3.03 |
Technical Indicators
Market Signals| Indicator | RAND | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 51.55 |
| Support Level | $10.03 | $0.93 |
| Resistance Level | $10.49 | $0.99 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 100.00 | 44.20 |
Price Performance
Historical ComparisonAbout RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.